Fig. 3From: CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trialKaplan-Meier analysis comparing the overall survival of patients from the CMAB009 plus irinotecan arm to those in the sequential-CMAB009 arm. OS, overall survival; HR, hazard ratio; CI, confidence intervalsBack to article page